Acerus Pharmaceuticals Corporation, often referred to simply as Acerus, is a Canadian biopharmaceutical company headquartered in Ontario, Canada. Founded in 2006, Acerus focuses on developing innovative therapeutic solutions primarily in the fields of men's health and hormone replacement therapy. The company has made significant strides with its flagship product, Natesto, a unique nasal testosterone replacement therapy that offers a convenient alternative to traditional methods. Acerus is committed to addressing unmet medical needs, positioning itself as a leader in the niche market of hormone therapies. With a strong emphasis on research and development, Acerus continues to expand its portfolio and enhance its market presence, striving to improve the quality of life for patients worldwide.
How does Acerus Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Acerus Pharmaceuticals Corporation's score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Acerus Pharmaceuticals Corporation, headquartered in Canada, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing greenhouse gas emissions. Companies in this sector are often encouraged to adopt science-based targets and engage in initiatives aimed at minimising their environmental impact. Acerus may be exploring similar pathways to enhance their sustainability practices, but specific details on their commitments or initiatives are not provided.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Acerus Pharmaceuticals Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.